Quest Diagnostics shares have underperformed the S&P 500 over the past year, rising 8.5% compared to the index's 25.4% return, even after the company reported strong first-quarter 2026 results. The stock gained 4.5% on April 21 following revenue of $2.9 billion, a 9.2% year-over-year increase, and adjusted diluted earnings per share of $2.50, up 13.1%. Management raised its full-year 2026 outlook to adjusted diluted EPS of $10.63 to $10.83. Analysts maintain a consensus Moderate Buy rating with a mean price target of $223, a 14.4% premium to current levels.
Quest Diagnostics IncorporatedStrong Q1 2026 results with revenue and EPS beats, raised full-year outlook, and analyst price target premium.
Thermo Fisher Scientific Inc